Exclusive Patent License for Respiratory Syncytial Virus and Parainfluenza Virus Vaccines

Summary

The National Institute of Allergy and Infectious Diseases is considering granting Medigen Vaccines Biologics Corp. an exclusive patent license to manufacture live respiratory syncytial virus and parainfluenza virus vaccines, following a review of the patents and patent applications listed in the notice.